On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading
On April 20, 2026, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration” (91 FR 16205) to Perpetual Biosciences, Inc.… Continue Reading
On March 2, 2026, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention… Continue Reading
On Monday, 12 January 2026 a division bench of the Delhi High Court comprised of Justice Hari Shankar and Justice Om Prakash Shukla approved the sale of a biosmilar version of nivolumab, a cancer drug marketed by the firm Zydus… Continue Reading
On Wednesday, 4 February 2026, Knowledge Ecology International (KEI) delivered this constituency statement on behalf of KEI, Health Action International, Global Health Council, World Council of Churches, and Oxfam International: WHO’s work in health emergencies. Our joint statement focused on… Continue Reading
On Tuesday, 3 February 2026, Knowledge Ecology International (KEI) delivered the following statement on universal health coverage. KEI will make three points. 1. There is inequality in access to small molecule drugs, far more inequality in access to biologic drugs,… Continue Reading
On Monday, 1 December 2025, Knowledge Ecology International (KEI) delivered the following statement on the 2025 European Health Data Spaces Regulation during the afternoon ession with Relevant Stakeholders which took place at WHO headquarters in Geneva from 16:45–17.15 CET. IGWG… Continue Reading
On October 20, 2025, Knowledge Ecology International (KEI) submitted comments to the NIH in response to the Federal Register notice titled, “Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors” (90 FR 47782) The… Continue Reading
On October 14, 2025, Knowledge Ecology International (KEI) provided the NIH with comments regarding the “Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Development of Zika Virus Strains for Use in Oncolytic Therapy” (90 FR 46414) to Advocate Aurora Research… Continue Reading